AGENDA

I. Call to order in accordance with New Jersey Open Public Meeting Act

II. Roll Call

III. Review of draft meeting summary for the June 29, 2011 meeting (pages 3-6; Tab1)

IV. Secretary’s report (pages 7-8; Tab 2)

V. New Business
   A. Proposed protocol for the efficient and safe use of telaprevir (Incivek®) (pages 9-10; Tab 3)
   B. Proposed protocol for the efficient use of fluticasone/salmeterol (Advair®) (pages 11-14; Tab 4)
   C. Review of NJ Mandatory Generic Substitution Drug Program (pages 15-18; Tab 5)

VI. Informational Highlights/Reports
   1. Molina Prior Authorization Report (pages 19-20; Tab 6)
   2. NJ HMO Reports 2nd Quarter 2011 (pages 21-24; Tab 7)
   3. DHS and DHSS Programs Top Drugs Report (pages 25 – 38; Tab 8)
   4. FDA Alerts: (pages 39-41; Tab 9)
      a. High dose simvastatin
      b. New maximum dosing for acetaminophen
      c. Varenicline (Chantix®) label change – risk of cardiovascular adverse events